摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-hydroxy-2-((pyrimidin-2-ylthio)methyl)-4H-pyran-4-one | 941868-82-2

中文名称
——
中文别名
——
英文名称
5-hydroxy-2-((pyrimidin-2-ylthio)methyl)-4H-pyran-4-one
英文别名
5-hydroxy-2-(pyrimidin-2-ylsulfanylmethyl)pyran-4-one
5-hydroxy-2-((pyrimidin-2-ylthio)methyl)-4H-pyran-4-one化学式
CAS
941868-82-2
化学式
C10H8N2O3S
mdl
MFCD09743102
分子量
236.251
InChiKey
RIGMECGKVLFSIH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    97.6
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    描述:
    5-hydroxy-2-((pyrimidin-2-ylthio)methyl)-4H-pyran-4-one4-硝基苯甲酰氯caesium carbonate 作用下, 以 乙腈 为溶剂, 以202 mg的产率得到5-[(4-硝基苯甲酰基)氧基]-2-[(2-嘧啶硫基)甲基]-4H-吡喃-4-酮
    参考文献:
    名称:
    SMALL MOLECULE ANTAGONISTS OF THE APELIN RECEPTOR FOR THE TREATMENT OF DISEASE
    摘要:
    本公开涉及化合物和治疗通过apelin介导的疾病的方法。
    公开号:
    US20140005181A1
  • 作为产物:
    参考文献:
    名称:
    Synthesis of kojic acid derivatives as secondary binding site probes of d-amino acid oxidase
    摘要:
    A series of kojic acid (5-hydroxy-2-hydroxymethyl-4H-pyran-4-one) derivatives were synthesized and tested for their ability to inhibit D-amino acid oxidase (DAAO). Various substituents were incorporated into kojic acid at its 2-hydroxymethyl group. These analogs serve as useful molecular probes to explore the secondary binding site, which can be exploited in designing more potent DAAO inhibitors. (c) 2013 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2013.04.062
点击查看最新优质反应信息

文献信息

  • SMALL MOLECULE ANTAGONISTS OF THE APELIN RECEPTOR FOR THE TREATMENT OF DISEASE
    申请人:Sanford-Burnham Medical Research Institute
    公开号:US20140005181A1
    公开(公告)日:2014-01-02
    The present disclosure relates to compounds and methods for treating a disease mediated by apelin.
    本公开涉及化合物和治疗通过apelin介导的疾病的方法。
  • Synthesis of kojic acid derivatives as secondary binding site probes of d-amino acid oxidase
    作者:Mithun Raje、Niyada Hin、Bridget Duvall、Dana V. Ferraris、James F. Berry、Ajit G. Thomas、Jesse Alt、Camilo Rojas、Barbara S. Slusher、Takashi Tsukamoto
    DOI:10.1016/j.bmcl.2013.04.062
    日期:2013.7
    A series of kojic acid (5-hydroxy-2-hydroxymethyl-4H-pyran-4-one) derivatives were synthesized and tested for their ability to inhibit D-amino acid oxidase (DAAO). Various substituents were incorporated into kojic acid at its 2-hydroxymethyl group. These analogs serve as useful molecular probes to explore the secondary binding site, which can be exploited in designing more potent DAAO inhibitors. (c) 2013 Elsevier Ltd. All rights reserved.
  • Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221) as a functional antagonist of the apelin (APJ) receptor
    作者:Patrick R. Maloney、Pasha Khan、Michael Hedrick、Palak Gosalia、Monika Milewski、Linda Li、Gregory P. Roth、Eduard Sergienko、Eigo Suyama、Eliot Sugarman、Kevin Nguyen、Alka Mehta、Stefan Vasile、Ying Su、Derek Stonich、Hung Nguyen、Fu-Yue Zeng、Arianna Mangravita Novo、Michael Vicchiarelli、Jena Diwan、Thomas D.Y. Chung、Layton H. Smith、Anthony B. Pinkerton
    DOI:10.1016/j.bmcl.2012.08.105
    日期:2012.11
    The recently discovered apelin/APJ system has emerged as a critical mediator of cardiovascular homeostasis and is associated with the pathogenesis of cardiovascular disease. A role for apelin/APJ in energy metabolism and gastrointestinal function has also recently emerged. We disclose the discovery and characterization of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221), a potent APJ functional antagonist in cell-based assays that is >37-fold selective over the closely related angiotensin II type 1 (AT1) receptor. ML221 was derived from an HTS of the similar to 330,600 compound MLSMR collection. This antagonist showed no significant binding activity against 29 other GPCRs, except to the kappa-opioid and benzodiazepinone receptors (<50/<70%I at 10 mu M). The synthetic methodology, development of structure-activity relationship (SAR), and initial in vitro pharmacologic characterization are also presented. (C) 2012 Elsevier Ltd. All rights reserved.
查看更多